Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results

被引：0

作者：

Voskoboynik, M. ^{[1
]}

Mileshkin, L. ^{[2
]}

Gan, H. ^{[3
]}

Millward, M. ^{[4
]}

Au-Yeung, G. ^{[2
]}

Meniawy, T. M. ^{[4
]}

Kichenadasse, G. ^{[5
]}

Zhang, K. ^{[6
]}

Zhang, M. ^{[7
]}

Mu, S. ^{[8
]}

Lickliter, J. D. ^{[1
]}

机构：

[1] Nucleus Network, Oncol, Melbourne, Vic, Australia

[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[3] Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia

[4] Linear Clin Res, Oncol, Nedlands, WA, Australia

[5] Flinders Med Ctr, Flinders Ctr Innovat Canc, Bedford Pk, SA, Australia

[6] BeiGene USA Inc, Biostat, Emeryville, CA USA

[7] BeiGene USA Inc, Clin Sci, Emeryville, CA USA

[8] BeiGene USA Inc, Clin Pharmacol, Emeryville, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

452PD

引用

页数：1